Hadasit Bio-Holdings

Press Releases

Sep. 1, 2016  -   הודעה על פרסום דוח הצעת מדף
Jun. 30, 2016  -   הודעה על כינוס אסיפה כללית מיוחדת של בעלי המניות של החברה
Jun. 21, 2016  -   Notification of the termination of ADS listing and trading
Jun. 8, 2016  -   Written Vote under the Companies Regulations
May. 30, 2016  -   הודעה על כינוס אסיפה כללית שנתית מיוחדת של בעלי המניות של החברה
Feb. 21, 2016  -   Written Vote under the Companies Regulations
Feb. 17, 2016  -   investment transaction in the Kahr Medical (2005) Company Ltd.
Feb. 14, 2016  -   Investment in Cell Cure Neurosciences Ltd.
Feb. 9, 2016  -   Investment in Cell Cure Neurosciences Ltd.
Feb. 3, 2016  -   Receipt of Helsinki Approval for Phase I/IIa Clinical Trial at Tel Hashomer by KAHR Medical Ltd. (“KAHR”)
Jan. 3, 2016  -   Investment in Kahr Medical
Dec. 20, 2015  -   Results of a Public Offering According to its Shelf Offer Report from December 16, 2015
Dec. 15, 2015  -   Investment Transaction in KAHR Medical (2005) Ltd.
Dec. 1, 2015  -   Helsinki Approval for Stage I/IIa Clinical Trials of KAHR Medical Ltd.
Nov. 18, 2015  -   Convertible Loan to Kahr Medical (2005) Ltd.
Nov. 11, 2015  -   D-Pharm: Recruiting the First Patient for the THR-18 Clinical Trial
Nov. 1, 2015  -   D Pharm Ltd. – Termination of CEO and Other Changes
Nov. 1, 2015  -   D Pharm Ltd. – Termination of CEO and Other Changes
Oct. 27, 2015  -   D Pharm Ltd. - Update Regarding Focus of Company Activity and Infrastructure Adaptation
Oct. 26, 2015  -   Termination of the Non-Binding Letter on Intend
Oct. 25, 2015  -   Results of the General and Special Meeting dated October 25, 2015
Oct. 13, 2015  -   Final Results of KAHR Medical Ltd. Pre-clinical Trials
Oct. 12, 2015  -   Written Vote under the Companies Regulations
Sep. 29, 2015  -   Receipt of FDA Approval of the Accelerated Regulator Track for the OpRegen® to Treat Dry Age-Related Macular Degeneration
Sep. 10, 2015  -   D Pharm Ltd. - Approval of THR-18 Trial Protocol
Sep. 2, 2015  -   Approval of Patent Registration in Japan - ProtAb Ltd.
Aug. 25, 2015  -   the Extension of the Term of the Non-Binding Letter of Intend For a Private Placement Agreement
Aug. 17, 2015  -   Public Offering Results according to Supplementary Prospectus and Supplementary Notice
Aug. 16, 2015  -   Share Offering
Jul. 30, 2015  -   Immediate Report – Kahr Medical (2005) Ltd.
Jul. 30, 2015  -   DPharm Ltd. – Receipt of Final Report for Clinical Trial Phase II
Jul. 14, 2015  -   Receipt of US Patent of CellCure Neurosciences
Jul. 6, 2015  -   Written Vote under the Companies Regulations
Jun. 29, 2015  -   Submitting an Application To Ethical Committees for Approval of Stage I/IIa Clinical Trials of KAHR Medical Ltd.
Jun. 28, 2015  -   Signing of a Non-Binding Letter of Intend For a Private Placement Agreement
Jun. 7, 2015  -   Reverse Split
May. 31, 2015  -   Immediate Report
May. 26, 2015  -   Annual general and special meeting Results- May 26, 2015
May. 5, 2015  -   Allowance of Patent in Australia - ProtAb Ltd
May. 1, 2015  -   The Results of Protab Ltd.’s Pre-Clinical Trials
Apr. 22, 2015  -   Voting Deed According to the Company Regulations
Apr. 14, 2015  -   Allowance of Patent in Israel - ProtAb Ltd
Apr. 4, 2015  -   Investment in CellCure Neurosciences Ltd.
Apr. 4, 2015  -   Convertible loan to KAHR Medical (2005) Ltd.
Mar. 30, 2015  -   Immediate Report Concerning the Results of a Public Offering According to a Shelf Offer from March 30, 2015
Mar. 21, 2015  -   Amendment of Enlivex’s Reports
Mar. 4, 2015  -   Amendment to Convertible Loan Agreement in KAHR Medical (2005) Ltd.
Feb. 17, 2015  -   Cell Cure Neurosciences Initiates Phase I/IIa Trial and Granted Key US Patent for Retinal Pigment Epithelial (RPE) Stem Cells
Feb. 16, 2015  -   Expiration of the Option of Teva Under the License Agreement with CellCure Neurosciences
Feb. 15, 2015  -   A voting paper based on the Companies Regulations
Feb. 15, 2015  -   Approval of 2015 Work Plan of D Pharm Ltd.
Feb. 12, 2015  -   The Signing of an Agreement for a Convertible Loan with KAHR Medical (2005) Ltd
Jan. 31, 2015  -   Extension of Option Period regarding the License Agreement between Teva and CellCure Neurosciences
Jan. 22, 2015  -   report from D Pharm Company Ltd. – the results of a rights issue
Jan. 1, 2015  -   Extension of Option Period regarding the License Agreement between Teva and CellCure Neurosciences
Dec. 27, 2014  -   Publication of a Shelf Registration Report for an offer by way of rights of D-Pharm LTD
Nov. 4, 2014  -   Initial results for clinical trial Phase IIa in THR-18 for D Pharm Ltd.
Oct. 6, 2014  -   IND Submission to the FDA of Cell Cure Neuroscience Ltd.
Sep. 23, 2014  -   Notice of results from meeting and request by the company
Aug. 13, 2014  -   Subjugation (lien) of the company's stocks held by the shareholder
May. 18, 2014  -   Enlivex- Completion Of Convertible Loan Recruitment
Feb. 18, 2014  -   Shareholders' Meeting to Approve New Directors
Dec. 24, 2013  -   Cell Cure, Enlivex and KAHR Medical to Receive NIS 12 Million (Over $3.4 Million USD) in Additional Government Grants
Dec. 16, 2013  -   Term Sheet Signed for Financing Enlivex
Nov. 28, 2013  -   Shareholders' Meeting to Approve New Directors, Payments to Directors, Outgoing CEO and New CEO
Sep. 9, 2013  -   KAHR Medical to Raise $2.5M at Pre-money Valuation of $13.5M
Aug. 12, 2013  -   Share Holder's Meeting to Approve Compensation Policy
May. 12, 2013  -   Cell Cure Neurosciences Ltd. Receives Significant Financing From the Israeli OCS and a BioTime Inc. Loan
Apr. 3, 2013  -   Enlivex Awarded Orphan Drug Status for ApoCell Treatment by the FDA
Feb. 4, 2013  -   KAHR expands and strengthens its intellectual property
Dec. 24, 2012  -   ProtAb and Enlivex receive CLAs
Nov. 11, 2012  -   Cell Cure Neurosciences Ltd. Receives Additional Financing From BioTime Inc.
Oct. 24, 2012  -   Enlivex Therapeutics Announces Positive Results in Completion of Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
Oct. 18, 2012  -   Einat Zisman, PhD, MBA appointed to the Hadasit Bio Holdings Board of Directors.
Oct. 16, 2012  -   Hadasit Bio-Holdings to Participate in Hadassah Centennial Convention
Oct. 16, 2012  -   Company’s ADR - HADSY - Now Blue Sky Exempt in Over 30 States
Sep. 12, 2012  -   Share holder's meeting to appoint new director
Sep. 4, 2012  -   Hadasit Bio raises 5.1 M NIS with over 99% exercise of rights
Aug. 13, 2012  -   Rights Issued to Current Share Holders and Warrant Holders
Aug. 1, 2012  -   General Share Holders Meeting Results
Jul. 30, 2012  -   Hadasit Bio Holdings Provides Convertible Loans to ProtAb Ltd. and Enlivex Ltd.
Jul. 19, 2012  -   Thrombotech Acquiered by D Pharm
Jun. 26, 2012  -   Annual shareholders meeting
Jun. 25, 2012  -   Hadasit Bio - Holdings files a shelf prospectus
Jun. 18, 2012  -   KAHR Medical raises over 10 million NIS
May. 30, 2012  -   Three directors were appointed to the company's board
May. 21, 2012  -   Thrombotech and D-Pharm Sign Purchase Agreement and Additional Investment
Apr. 5, 2012  -   BioMarCare's $900k BIRD grant approved
Mar. 27, 2012  -   A Strategic Investment in BioMarCare Technologies Inc.
Mar. 13, 2012  -   HBL Share Holders Meeting and Extension of Options' Maturation Date
Mar. 7, 2012  -   Two portfolio companies receive OCS approvals
Feb. 28, 2012  -   Thrombotech Ltd. Receives IND Approval From the FDA
Feb. 28, 2012  -   Thrombotech Ltd. Approved for Phase IIa in the U.S.A.
Feb. 23, 2012  -   Thrombotech Ltd. Buyout Negotiations With D-Pharm Ltd
Jan. 15, 2012  -   Enlivex has completed patient enrollment in its Phase I/II clinical trial
Jan. 10, 2012  -   Thrombotech Completes Additional Financing Round of $1.4 million
Nov. 27, 2011  -   Recommendation to terminate Verto’s activity - not expected to affect company.
Nov. 14, 2011  -   4 portfolio companies have received government grants for over 10 M NIS in 2011
Oct. 30, 2011  -   BioMarCare receives approval for use of 400 samples from the Hadassah Medical Center
Jul. 6, 2011  -   BioMarCare Ltd. receives initial approval for a grant from the BIRD Foundation
Jul. 3, 2011  -   HBL announces that Thrombotech has begun its Phase IIa clinical trial
Jun. 27, 2011  -   Hadasit Bio-Holdings Begins Trading in U.S. through Launch of ADR
Jun. 20, 2011  -   BNY Mellon Appointed as Depositary Bank by Hadasit Bio-Holdings, Ltd.
Jun. 19, 2011  -   HBL announces an ADS trading program in the United States (OTCBB:HADSY)
Apr. 14, 2011  -   KAHR Medical to Raise $ 3 M for Development of Novel Cancer and Autoimmune Disease Drugs
$2 million will be invested by the European drug giant Sanofi-Aventis
Mar. 9, 2011  -   Poalim Sahar initiates coverage on HBL
Analyst sets target share price at 2.1 NIS (100% upside)
Mar. 6, 2011  -   BioMarCare financing and clinical trial
BioMarCare receives financing and Helsinki approval for clinical trial
Dec. 26, 2010  -   Hadasit Bio-Holdings facilitates foreign investment in the traded stock (TASE:HDST)
We are happy to provide an easy and convenient investment tool for our international investors
Oct. 10, 2010  -   HBL's subsidiary- CellCure makes the deal of the year
TEVA, BioTime and HBL invest $7.1 M. and sign an exclusive license option agreement with TEVA
Sep. 28, 2010  -   HBL and BioMarCare get positive PR from top IBI analyst in Globes
Investment recommendations from Elah Alkalay VP BD at IBI
Aug. 31, 2010  -   Report by Globes on TASE Offering
"Hadasit Bio Holdings Raises NIS 11.5m in TASE Offering"
Aug. 31, 2010  -   Successful Public Offering
HBL Announces a Successful Public Offering on the TASE - Over 11 Million NIS Raised
Aug. 24, 2010  -   Another Major Achievement for Hadasit Bio Holdings (Thrombotech completes phase I)
Thrombotech, a subsidiary of Hadasit Bio Holdings, successfully completed Phase I trial
Aug. 19, 2010  -   Q2 2010 report (capital gain of 13 million NIS)
The company reports first substantial capital gain of 13 million NIS
Aug. 16, 2010  -   Exclusive Licensing Agreement
BioMarCare Technologies, a subsidiary of Hadasit Bio-Holdings, Has Signed an Exclusive Licensing Agreement with Hadasit for the Commercialization of an Innovative Marker Enabling Early Detection of Cancer
Jul. 29, 2010  -   Spotlight on HBL - in "Globes"
"The TASE BioMed Index's Favorite Seeking Partnerships"
Jun. 14, 2010  -   3 of HBL's Portfolio Companies Appear in "Israel's Most Promising BioTech Statups" List
ProtAb, KAHR and CellCure included in the list
Jun. 13, 2010  -   From Test Tube to Bedside
Israel's only hospital affiliated biopark, located in Jerusalem, helps doctors conduct research
Apr. 19, 2010  -   "Swimming Against The Current"
9 Stocks on TASE Post Gains Even When the Market Doesn't
Apr. 13, 2010  -   Clal Biotechnology, Pontifax and Hadasit Bio-Holdings to invest $ 4 million in ProtAb, a wholly owned Hadasit Bio-Holdings portfolio company
The company is developing a novel monoclonal antibody for the treatment of Rheumatoid Arthritis and other autoimmune diseases such as Crohn’s Disease
Mar. 28, 2010  -   Hadassah Breakthrough Increases the Potential to Produce the Large Quantities of Human Embryonic Stem Cells Required For Transplantation
Mar. 19, 2010  -   Hadasit - One of "10 Promising Stocks for 2010"
Mar. 11, 2010  -   Hadasit Bio Holdings Exploits Its Competitive Advantage
As published in "Globes", March 10th, 2010
Mar. 3, 2010  -   Small But Promising Companies
New BioMed Index Attracts Investors in Israel Life Sciences
Jan. 24, 2010  -   Tel Aviv Stock Exchange to Launch BioMed Index
38 BioMed Companies on TASE. Index to Allow New Investment Vehicles
Dec. 24, 2009  -   KAHR Medical Raises 1.5 M Sheqels from Hadasit Bio-Holdings, Moves Towards Clinical Trial of Immune-system Diseases and Cancer
Invited to Present Preclinical Results at Major Scientific Conferences in Europe and the United States
Dec. 6, 2009  -   ProtAb, a Wholly Owned Subsidiary of Hadasit Bio-Holdings, Attracts Funding and Initiates the Manufacturing Process of its Lead Antibody in Preparation for Clinical Trials
Nov. 17, 2009  -   Hadasit Bio-Holdings Expands Activity to Diagnostic Markers for Cancer and Sets Up BioMarCare Technologies
The new company has begun a clinical trial of the first marker, for detection of various stages of breast cancer. HBL will inject 1.1 million NIS to bring the trial to completion.
Sep. 15, 2009  -   "An Innovation Factory in the Medical Field"
HBL bridges the gap between hospital research and industry
Sep. 1, 2009  -   Innovation Powerhouse Applies a New Model For Commercialization
How hadassah is leading Israel’s medical research
Jul. 6, 2009  -   Jerusalem Mayor Nir Barkat Visits BioTechnology Park at Hadassah Ein Kerem
Mayor calls the Jerusalem BioPark a central element in the making of Jerusalem
Feb. 26, 2009  -   KAHR's Third Generation Biologics Attract Financing
Published in BioWorld Today, Feb. 19th, 2009
 
 

Press Releases Archive